Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 19 | 2026 | 674 | 3.140 |
Why?
|
| Rotavirus Vaccines | 14 | 2024 | 60 | 2.500 |
Why?
|
| Rotavirus Infections | 17 | 2024 | 278 | 2.430 |
Why?
|
| Influenza Vaccines | 10 | 2025 | 481 | 2.260 |
Why?
|
| Hospitalization | 35 | 2026 | 1874 | 1.820 |
Why?
|
| Respiratory Tract Infections | 11 | 2025 | 278 | 1.790 |
Why?
|
| Gastroenteritis | 13 | 2025 | 307 | 1.730 |
Why?
|
| Vaccination | 20 | 2024 | 1004 | 1.570 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 6 | 2025 | 185 | 1.420 |
Why?
|
| Rotavirus | 10 | 2024 | 363 | 1.150 |
Why?
|
| Infant | 52 | 2026 | 12771 | 0.980 |
Why?
|
| Immunization Programs | 5 | 2020 | 66 | 0.950 |
Why?
|
| Enterovirus Infections | 5 | 2025 | 48 | 0.920 |
Why?
|
| Child | 56 | 2026 | 25101 | 0.820 |
Why?
|
| Respiratory Syncytial Virus Infections | 5 | 2025 | 357 | 0.800 |
Why?
|
| Child, Preschool | 45 | 2026 | 14347 | 0.780 |
Why?
|
| Population Surveillance | 6 | 2025 | 394 | 0.690 |
Why?
|
| Case-Control Studies | 18 | 2024 | 3314 | 0.680 |
Why?
|
| Antiviral Agents | 5 | 2026 | 757 | 0.660 |
Why?
|
| United States | 39 | 2026 | 11310 | 0.640 |
Why?
|
| Reassortant Viruses | 3 | 2016 | 28 | 0.620 |
Why?
|
| Epidemiological Monitoring | 3 | 2018 | 61 | 0.620 |
Why?
|
| Enterovirus D, Human | 3 | 2025 | 11 | 0.560 |
Why?
|
| Arbovirus Infections | 1 | 2018 | 30 | 0.560 |
Why?
|
| Respiratory Syncytial Virus, Human | 4 | 2025 | 219 | 0.560 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 6 | 2025 | 122 | 0.530 |
Why?
|
| Prospective Studies | 16 | 2025 | 6214 | 0.520 |
Why?
|
| Fever | 2 | 2024 | 309 | 0.510 |
Why?
|
| Humans | 80 | 2026 | 126753 | 0.500 |
Why?
|
| Adolescent | 31 | 2026 | 20002 | 0.500 |
Why?
|
| Reminder Systems | 2 | 2016 | 60 | 0.490 |
Why?
|
| Immunization | 2 | 2021 | 300 | 0.480 |
Why?
|
| Seasons | 7 | 2025 | 309 | 0.430 |
Why?
|
| Picornaviridae Infections | 2 | 2025 | 49 | 0.430 |
Why?
|
| Infant, Newborn | 20 | 2025 | 8347 | 0.420 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2025 | 70 | 0.420 |
Why?
|
| Female | 47 | 2026 | 68330 | 0.410 |
Why?
|
| Enterovirus | 2 | 2024 | 52 | 0.390 |
Why?
|
| Texas | 12 | 2021 | 3551 | 0.390 |
Why?
|
| Male | 45 | 2026 | 62543 | 0.380 |
Why?
|
| Vaccination Coverage | 2 | 2025 | 36 | 0.370 |
Why?
|
| Viruses | 2 | 2024 | 113 | 0.370 |
Why?
|
| Antibodies, Viral | 1 | 2018 | 1131 | 0.370 |
Why?
|
| Immunization Schedule | 5 | 2024 | 104 | 0.360 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2025 | 541 | 0.360 |
Why?
|
| Hospitals, Pediatric | 6 | 2024 | 775 | 0.350 |
Why?
|
| Acute Disease | 6 | 2025 | 1135 | 0.340 |
Why?
|
| Emergency Service, Hospital | 7 | 2024 | 1166 | 0.330 |
Why?
|
| Information Systems | 1 | 2010 | 29 | 0.330 |
Why?
|
| Autism Spectrum Disorder | 3 | 2021 | 423 | 0.310 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 658 | 0.300 |
Why?
|
| Systemic Inflammatory Response Syndrome | 4 | 2023 | 200 | 0.300 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 316 | 0.290 |
Why?
|
| Disease Outbreaks | 2 | 2021 | 307 | 0.290 |
Why?
|
| Vaccines, Attenuated | 8 | 2022 | 173 | 0.280 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2024 | 478 | 0.280 |
Why?
|
| Genotype | 7 | 2025 | 2595 | 0.280 |
Why?
|
| Rhinovirus | 2 | 2025 | 60 | 0.280 |
Why?
|
| Paramyxoviridae Infections | 2 | 2025 | 46 | 0.270 |
Why?
|
| Vaccines | 2 | 2023 | 381 | 0.260 |
Why?
|
| Pandemics | 6 | 2026 | 1135 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2025 | 2975 | 0.250 |
Why?
|
| Pediatrics | 1 | 2016 | 1202 | 0.250 |
Why?
|
| Mothers | 3 | 2024 | 363 | 0.250 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 533 | 0.230 |
Why?
|
| Adenovirus Infections, Human | 1 | 2025 | 51 | 0.230 |
Why?
|
| Adenoviruses, Human | 1 | 2025 | 93 | 0.230 |
Why?
|
| Professionalism | 1 | 2024 | 45 | 0.210 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2024 | 15 | 0.210 |
Why?
|
| Feces | 7 | 2020 | 702 | 0.200 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 94 | 0.200 |
Why?
|
| Influenza B virus | 4 | 2025 | 98 | 0.200 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 149 | 0.200 |
Why?
|
| Parents | 5 | 2021 | 1072 | 0.200 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 29 | 0.200 |
Why?
|
| Pregnancy | 6 | 2025 | 7373 | 0.190 |
Why?
|
| Caliciviridae Infections | 1 | 2025 | 279 | 0.190 |
Why?
|
| Prenatal Care | 1 | 2025 | 346 | 0.190 |
Why?
|
| Metapneumovirus | 1 | 2022 | 47 | 0.190 |
Why?
|
| Norovirus | 1 | 2025 | 279 | 0.180 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2022 | 35 | 0.180 |
Why?
|
| Turbinates | 1 | 2021 | 13 | 0.180 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 2021 | 2 | 0.180 |
Why?
|
| RNA, Viral | 2 | 2021 | 510 | 0.180 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 167 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 44 | 0.170 |
Why?
|
| Mobile Health Units | 1 | 2020 | 27 | 0.160 |
Why?
|
| Virus Diseases | 1 | 2022 | 269 | 0.160 |
Why?
|
| Outpatients | 1 | 2021 | 254 | 0.160 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2020 | 115 | 0.150 |
Why?
|
| Family Health | 1 | 2020 | 248 | 0.150 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2019 | 16 | 0.150 |
Why?
|
| Antigens, Viral | 3 | 2024 | 389 | 0.150 |
Why?
|
| Communicable Diseases, Imported | 1 | 2018 | 6 | 0.140 |
Why?
|
| Child, Hospitalized | 3 | 2026 | 77 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2025 | 1508 | 0.140 |
Why?
|
| Bites and Stings | 1 | 2018 | 27 | 0.140 |
Why?
|
| Family Characteristics | 3 | 2025 | 96 | 0.140 |
Why?
|
| Chikungunya Fever | 1 | 2018 | 32 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 880 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2021 | 395 | 0.140 |
Why?
|
| Cost of Illness | 3 | 2025 | 283 | 0.130 |
Why?
|
| Travel | 1 | 2018 | 123 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.130 |
Why?
|
| Dengue | 1 | 2018 | 120 | 0.130 |
Why?
|
| Autistic Disorder | 1 | 2020 | 363 | 0.130 |
Why?
|
| West Nile Fever | 1 | 2018 | 137 | 0.120 |
Why?
|
| Coinfection | 1 | 2018 | 185 | 0.120 |
Why?
|
| Developmental Disabilities | 1 | 2021 | 718 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2023 | 781 | 0.120 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 25 | 0.120 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 3662 | 0.120 |
Why?
|
| Genome, Viral | 1 | 2016 | 153 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 361 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.120 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2016 | 139 | 0.110 |
Why?
|
| Database Management Systems | 1 | 2014 | 27 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 237 | 0.110 |
Why?
|
| Phylogeny | 1 | 2016 | 686 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2010 | 26 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2024 | 2537 | 0.100 |
Why?
|
| Forecasting | 1 | 2014 | 355 | 0.100 |
Why?
|
| Patient Acuity | 2 | 2022 | 63 | 0.090 |
Why?
|
| Adult | 4 | 2025 | 30410 | 0.080 |
Why?
|
| Hospital Information Systems | 1 | 2010 | 42 | 0.080 |
Why?
|
| Serum | 1 | 2010 | 43 | 0.080 |
Why?
|
| Time Factors | 3 | 2025 | 6134 | 0.080 |
Why?
|
| Young Adult | 2 | 2025 | 9665 | 0.070 |
Why?
|
| Informed Consent | 1 | 2010 | 337 | 0.070 |
Why?
|
| Absenteeism | 1 | 2024 | 18 | 0.060 |
Why?
|
| Vaccination Refusal | 1 | 2024 | 19 | 0.060 |
Why?
|
| Vomiting | 1 | 2025 | 99 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 4954 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2024 | 39 | 0.050 |
Why?
|
| Risk Factors | 3 | 2025 | 10555 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2023 | 7 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 2065 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2024 | 163 | 0.050 |
Why?
|
| Crowding | 1 | 2023 | 12 | 0.050 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2022 | 32 | 0.050 |
Why?
|
| Coronavirus | 1 | 2022 | 25 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 783 | 0.050 |
Why?
|
| Oseltamivir | 1 | 2021 | 19 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2024 | 401 | 0.050 |
Why?
|
| Life Support Care | 1 | 2022 | 48 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2022 | 120 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 114 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 250 | 0.040 |
Why?
|
| Transients and Migrants | 1 | 2020 | 28 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 146 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 428 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 2789 | 0.040 |
Why?
|
| Urban Population | 2 | 2010 | 236 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2019 | 76 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 422 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1398 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 497 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1222 | 0.030 |
Why?
|
| Critical Illness | 1 | 2022 | 604 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 2591 | 0.030 |
Why?
|
| Asthma | 1 | 2025 | 764 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 988 | 0.030 |
Why?
|
| Poverty | 1 | 2020 | 431 | 0.030 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 13 | 0.030 |
Why?
|
| Chickenpox Vaccine | 1 | 2016 | 14 | 0.030 |
Why?
|
| Haemophilus Vaccines | 1 | 2016 | 32 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1559 | 0.030 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2016 | 14 | 0.030 |
Why?
|
| Hepatitis B Vaccines | 1 | 2016 | 44 | 0.030 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2016 | 35 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3586 | 0.030 |
Why?
|
| Cattle | 1 | 2016 | 537 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 315 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 541 | 0.030 |
Why?
|
| Software Design | 1 | 2014 | 21 | 0.030 |
Why?
|
| Saliva | 1 | 2015 | 129 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2014 | 44 | 0.030 |
Why?
|
| Premature Birth | 1 | 2019 | 402 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2014 | 139 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 168 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 5114 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 409 | 0.020 |
Why?
|
| Presumed Consent | 1 | 2010 | 4 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 899 | 0.020 |
Why?
|
| Hospitals, Maternity | 1 | 2010 | 8 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3584 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 235 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 154 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2013 | 396 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 422 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 20344 | 0.020 |
Why?
|
| Middle Aged | 1 | 2025 | 27697 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 2225 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3262 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1536 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 5941 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2015 | 12546 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 33051 | 0.010 |
Why?
|